Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has shared an announcement.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced the full exercise of the Over-allotment Option, resulting in the issuance of 33,677,800 H Shares at HK$44.05 per share. This move, part of the company’s Global Offering, indicates strong demand and successful stabilization efforts, with the stabilization period ending on June 19, 2025. The listing of these shares on the Hong Kong Stock Exchange is set to commence on June 24, 2025, potentially enhancing the company’s market presence and investor confidence.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a pharmaceutical company based in the People’s Republic of China. It is involved in the development, manufacturing, and distribution of pharmaceutical products, with a focus on innovative drugs and therapies.
Average Trading Volume: 8,217,135
Current Market Cap: HK$359.1B
Find detailed analytics on 1276 stock on TipRanks’ Stock Analysis page.